The failure of antiviral therapy for chronic hepatitis B can involve both virological breakthrough and genotypic resistance. A study of the failure of nucleoside analogue therapy suggests that drug-resistant mutants are not solely responsible for treatment failure. Suboptimal treatment adherence might also have an important role.
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Soriano, V., Perelson, A. S. & Zoulim, F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62, 1–4 (2008).
Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).
Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).
Hongthanakorn, C. et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice. Hepatology doi:10.1002/hep.2 4318.
Snow-Lampart, A. et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53, 763–773 (2011).
Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422–430 (2010).
Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487–497 (2005).
Chotiyaputta, W., Peterson, C., Ditah, F. A., Goodwin, D. & Lok, A. S. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis. B. J. Hepatol. 54, 12–18 (2011).
Patterson, S. J. et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis. B. Gut 60, 247–254 (2011).
Lee, P. K., Kieffer, T. L., Siliciano, R. F. & Nettles, R. E. HIV-1 viral load blips are of limited clinical significance. J. Antimicrob. Chemother. 57, 803–805 (2006).
F. Zoulim has been a Consultant for Bristol–Myers Squibb, Gilead and Novartis. He has also been on the Speakers' Bureau for Bristol–Myers Squibb and Gilead and has received grant/research support from Gilead and Roche.
About this article
Cite this article
Zoulim, F. Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 8, 366–367 (2011). https://doi.org/10.1038/nrgastro.2011.104
Current Opinion in Virology (2016)
Infectious Diseases and Therapy (2016)
Reviews in Medical Virology (2016)
Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains
Antimicrobial Agents and Chemotherapy (2014)
Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance
Liver International (2013)